| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/30/2009 | WO2009054994A2 Use of compounds activating sirt-3 for mimicking exercise |
| 04/30/2009 | WO2009054967A2 Compositions for delivery of glycopeptide antibiotics |
| 04/30/2009 | WO2009054725A2 Means and methods for counteracting muscle disorders |
| 04/30/2009 | WO2009054483A1 Drug containing salusin-β |
| 04/30/2009 | WO2009054471A1 Immune response inducer |
| 04/30/2009 | WO2009054470A1 Immune response inducer and use thereof |
| 04/30/2009 | WO2009054463A1 Pharmaceutical composition containing lipophilic il-2 production inhibitor |
| 04/30/2009 | WO2009054435A1 Polypeptide having enhanced effector function |
| 04/30/2009 | WO2009054433A1 Cell for use in the production of exogenous protein, and production process using the cell |
| 04/30/2009 | WO2009054361A1 Hair growth promoter |
| 04/30/2009 | WO2009054321A1 IMMUNOGLOBULIN IgA CLASS SWITCHING AGENT |
| 04/30/2009 | WO2009054128A1 Method for efficient production of monocyte-derived multipotent cell (momc) |
| 04/30/2009 | WO2009053828A2 P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors |
| 04/30/2009 | WO2009053725A2 Peptides and uses thereof |
| 04/30/2009 | WO2009053637A2 Anti-ricin antibody |
| 04/30/2009 | WO2009053597A2 Novel method for preparing nanoparticles covered with an organic stabilising layer coupled to targeting ligands |
| 04/30/2009 | WO2009053536A2 Splice variants of gdnf and uses thereof |
| 04/30/2009 | WO2009053535A2 Peptide vaccine for influenza virus |
| 04/30/2009 | WO2009053487A2 Proteins that stimulate the secretion of satiety hormones |
| 04/30/2009 | WO2009053467A2 The use of a non-glycanated polypeptide for treating a cancer |
| 04/30/2009 | WO2009053368A1 Single ifn-beta fused to a mutated igg fc fragment |
| 04/30/2009 | WO2009053106A1 Parathyroid hormone formulations and uses thereof |
| 04/30/2009 | WO2009053064A1 Sdf-1-based glycosaminoglycan antagonists and methods of using same |
| 04/30/2009 | WO2009052942A2 Stabilization of hydrophobic protein therapeutic agents |
| 04/30/2009 | WO2009052623A1 Therapeutic and diagnostic methods using tim-3 |
| 04/30/2009 | WO2009052588A1 Cytokine muteins |
| 04/30/2009 | WO2009052561A1 Compositions and methods for manipulating an immune response |
| 04/30/2009 | WO2009033733A3 Use of apeptide as a therapeutic agent |
| 04/30/2009 | WO2009032978A3 Compositions and methods for diagnosing and treating urinary tract infections |
| 04/30/2009 | WO2009027478A3 A method of removing preservatives from a liquid pharmaceutical preparation |
| 04/30/2009 | WO2009022988A3 Vhz for diagnosis and treatment of cancer |
| 04/30/2009 | WO2009020994A3 Ultrasound and microbubbles in ocular diagnostics and therapies |
| 04/30/2009 | WO2009017809A3 Screening methods using g-protein coupled receptors and related compositions |
| 04/30/2009 | WO2009017775A3 Process for the preparation of a polypeptide |
| 04/30/2009 | WO2009014624A3 Nrf2 inducers for treating epidermolysis bullosa simplex |
| 04/30/2009 | WO2009010957A3 Heparanase c-terminal domain, sequences derived therefrom, substances directed against said domain and uses thereof as modulators of heparanase biological activity |
| 04/30/2009 | WO2009010270A3 Purification of pegylated polypeptides |
| 04/30/2009 | WO2009009115A3 Liposome compositions for treatment of hepatitis c |
| 04/30/2009 | WO2008157483A3 Polypeptides and methods of use |
| 04/30/2009 | WO2008147867A3 Cross-linked collagen and uses thereof |
| 04/30/2009 | WO2008137901A9 Methods for treating and preventing gi syndrome and graft versus host disease |
| 04/30/2009 | WO2008128342A9 Composition for enhancing bone formation |
| 04/30/2009 | WO2008119042A3 Combination of blys inhibition and/or april inhibition and immunnosuppressants for treatment of autoimmune disease |
| 04/30/2009 | WO2008109068A3 A conjugate of insulin and vitamin b12 for oral delivery |
| 04/30/2009 | WO2008097249A3 Method for the treatment of anthrax toxicity |
| 04/30/2009 | WO2008094969A3 Combination therapy with angiogenesis inhibitors |
| 04/30/2009 | WO2008085794A3 Methods and compositions related to clot binding compounds |
| 04/30/2009 | WO2008062436A4 Antimicrobial derivatives of anacardic acid and process for preparing the same |
| 04/30/2009 | WO2008062420A3 Use of glucagon and insulin in methods and compositions for the treatment of acute brain injury and neurodegenerative disorders |
| 04/30/2009 | WO2008061209A3 G protein coupled receptors and uses thereof |
| 04/30/2009 | WO2008054465A3 Method to reduce the risk and/or severity of anthrax infection |
| 04/30/2009 | WO2008001380A3 Method of treatment of age-related macular degeneration |
| 04/30/2009 | WO2008001379A3 Activated myeloid cells for promoting tissue repair and detecting damaged tissue |
| 04/30/2009 | WO2007130073A3 Novel reagents for transfection of eukaryotic cells |
| 04/30/2009 | WO2007062060A3 Methods and compositions using substance p to promote wound healing |
| 04/30/2009 | WO2007061942A3 Compositions for disrupting and inhibiting reconstitution of wound biofilm |
| 04/30/2009 | WO2007059047A3 Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements |
| 04/30/2009 | WO2007059010A3 Stem cell factor therapy for tissue injury |
| 04/30/2009 | WO2007056352A3 Compositions and methods for controlling tissue factor signaling specificity |
| 04/30/2009 | WO2007048073A3 Methods and compositions for treatment of cancers with hoxb4 |
| 04/30/2009 | WO2007047899A3 Antimicrobial decapeptide oral hygiene treatment |
| 04/30/2009 | WO2007047764A3 Wt1 hla class ii-binding peptides and compositions and methods comprising same |
| 04/30/2009 | WO2007047408A3 Promac signature application |
| 04/30/2009 | WO2007041614A3 Long acting vegf inhibitors and methods of use |
| 04/30/2009 | WO2007038619A3 Proteinaceous pharmaceuticals and uses thereof |
| 04/30/2009 | WO2007030792A3 Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
| 04/30/2009 | WO2007029262A3 Compositions and methods using same for the detection of viruses |
| 04/30/2009 | WO2007029249A3 Oligoribonucleotides and methods of use thereof for treatment of cardiovascular diseases |
| 04/30/2009 | WO2007029238A3 Methods and compositions for oral administration of proteins |
| 04/30/2009 | WO2007027916A9 Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| 04/30/2009 | WO2007019401A3 Polypeptides useful for appetite suppression |
| 04/30/2009 | WO2007005995A3 Compositions for buccal delivery of human growth hormone |
| 04/30/2009 | WO2006130718A3 Synthetic peptide inhibitors of thrombin |
| 04/30/2009 | WO2006127978A3 Compositions and methods for the treatment of cancer |
| 04/30/2009 | WO2006105516A3 Compositions and methods for diagnosing and treating neuropsychiatric disorders |
| 04/30/2009 | WO2006088906A3 Modulation of muc1 activity |
| 04/30/2009 | WO2006054309A3 Debriding composition from bromelain |
| 04/30/2009 | WO2006047638A3 Modulators of epha2 and ephrina1 for the treatment of fibrosis-related disease |
| 04/30/2009 | WO2006014567A3 Pleural effusion treatment device, method and material |
| 04/30/2009 | WO2004092199A3 Method for identifying modulators of g protein coupled receptor signaling |
| 04/30/2009 | WO2004071436A3 The use of gcc ligands |
| 04/30/2009 | US20090112190 Medical or veterinary digestive tract utilization systems and methods |
| 04/30/2009 | US20090111982 Macrocyclic compounds as inhibitors of viral replication |
| 04/30/2009 | US20090111970 used to regulate an immune response in an animal; inhibits TF-1 cell proliferation activity |
| 04/30/2009 | US20090111969 Macrocyclic compounds as inhibitors of viral replication |
| 04/30/2009 | US20090111767 Modulation of insulin like growth factor i receptor expression |
| 04/30/2009 | US20090111758 Use of therapeutically useful peptides |
| 04/30/2009 | US20090111757 Hcv protease inhibitors |
| 04/30/2009 | US20090111756 Monomethylvaline Compounds Having Phenylalanine Carboxy Modifications at the C-Terminus |
| 04/30/2009 | US20090111755 Methods for the use of inhibitors of antigen presentation by mhc class ii molecules |
| 04/30/2009 | US20090111754 Selective Inhibitors of Nuclear Factor KappaB Activation and Uses Thereof |
| 04/30/2009 | US20090111753 Nogo-A Polypeptide Fragments, Variant Nogo Receptor-1 Polypeptides, and Uses Thereof |
| 04/30/2009 | US20090111752 Stable Formulation of Modified GLP-1 |
| 04/30/2009 | US20090111751 Method of Removing a Non-Metallic Protein Inhibitor From a Liquid Pharmaceutical Preparation |
| 04/30/2009 | US20090111750 Keratin derivatives and methods of making the same |
| 04/30/2009 | US20090111749 Delivery of Active Agents |
| 04/30/2009 | US20090111748 Fibroblast growth factor-2 promotes neurogenesis and neuroprotection and prolongs survival in huntington's disease |
| 04/30/2009 | US20090111747 Anti-Diabetic or Anti-Hypertensive Dietary Supplement |
| 04/30/2009 | US20090111746 Modulating toll-like receptor activity |
| 04/30/2009 | US20090111745 Plad Domain Peptides With Increased Serum Half Life Due To Conjugation To Domain Antibodies |